CSBio CSBio

X
[{"orgOrder":0,"company":"Cristal Therapeutics","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Cristal Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein.

            Lead Product(s): COVID-19 Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Intravacc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY